

Product Name : CX-4945

Synonyms : Silmitasertib; CX4945


Cat No. : M10065

CAS Number : 1009820-21-6

Molecular Formula : C₁₉H₁₂ClN₃O₂

Formula Weight : 349.77

Chemical Name : Benzo[c]-2,6-naphthyridine-8-carboxylic acid, 5-[(3-chlorophenyl)amino]-



Description : CX-4945 (Silmitasertib, CX4945) is a potent, selective, orally bioavailable, ATP-competitive inhibitor of protein kinase Casein Kinase 2 (CK2) with K_i of 0.38 nM, CK2 α IC₅₀ of 1 nM; displays good selectivity profile against a panel of 238 kinases; attenuates PI3K/Akt signaling, blocks CK2-dependent HIF-1 α transcription, caused cell cycle arrest and selectively induces apoptosis in cancer cells relative to normal cells; exhibits antitumor efficacy in murine xenograft models. Blood Cancer Phase 2 Clinical

Pathway : Metabolic Enzyme/Protease

Target : Casein Kinase

Receptor : CK2

Solubility : DMSO: ≥ 35 mg/mL

SMILES : O=C(C1=CC=C2C(N=C(NC3=CC=CC(Cl)=C3)C4=C2C=NC=C4)=C1)O

Storage : (-20°C)

Stability : ≥ 2 years

Reference :

1. Pierre F, et al. J Med Chem. 2011 Jan 27;54(2):635-54. | 2. Siddiqui-Jain A, et al. Cancer Res. 2010 Dec 15;70(24):10288-98. | 3. Siddiqui-Jain A, et al. Mol Cancer Ther. 2012 Apr;11(4):994-1005.